Tue, 20 Oct 2026
04:56:50 pm
Rudransh Sangwan
Published at: October 8, 2026, 6:23 PM
Synopsis
Honasa Consumer shares rose 12% after its Q2 update. HDFC Securities expects strong brand growth, wider offline reach and better margins.

HDFC Securities has maintained its "Buy" rating on Honasa Consumer, the parent company of Mamaearth, with a target price of Rs 550. The brokerage expects growth across Mamaearth, The Derma Co. and Honasa's newer brands to support the business.
Honasa Consumer shares rose 12% on Tuesday after the company's second quarter business update. The stock's six month return reached 54%, while its year to date gain stood at 63%.
The company expects Q2FY27 net sales value growth in the early thirties, supported by growth across its focus brands and categories. It also expects an early double digit operating margin during the quarter.
Loading chart...
HDFC Securities said Honasa Consumer is showing growth across its two largest brands, Mamaearth and The Derma Co. The brokerage said the annual recurring revenue of both brands has crossed Rs 10 billion.
The brokerage also pointed to faster growth through offline channels. Mamaearth and The Derma Co. are expanding their reach through chemists as well as cosmetics retailers, giving the company a wider physical distribution network.
Management has set a target of reaching 300,000 offline direct reach outlets by FY31, compared with around 120,000 outlets currently. Honasa has also strengthened its modern trade presence, which now has 95% penetration.
The development is relevant to the broader stock market theme around consumer companies expanding their distribution networks. WeloMoney has also tracked Honasa Consumer among stocks to watch, giving readers another view of the company's market position.
Honasa Consumer has built a portfolio of established and younger personal care brands. Along with Mamaearth and The Derma Co., its brands include Aqualogica, Dr. Sheth's, BBlunt, Reginald and Staze.
The brokerage said Aqualogica, Dr. Sheth's, BBlunt and Reginald are each positioned in the Rs 1 billion to Rs 2 billion revenue range. HDFC Securities expects these brands to grow further across channels by using the distribution approach developed by Mamaearth and The Derma Co.
Reginald has drawn attention from the brokerage because of its focus on male skincare and its relatively limited market presence. HDFC Securities expects the brand to have scope to accelerate its growth.
Management has also reported encouraging traction for Staze, which is approaching Rs 1 billion in revenue.
The company is expanding across personal care categories while established FMCG companies are focusing on fewer, larger brands. Honasa's strategy remains centred on emerging consumer trends and product efficacy.
The main figures from the brokerage view and the company's business update are:
| Particulars | Details |
|---|---|
| HDFC Securities target price | Rs 550 |
| Brokerage rating | Buy |
| Six month stock return | 54% |
| Year to date stock gain | 63% |
| Tuesday share price move | 12% |
| Mamaearth and The Derma Co. ARR | Above Rs 10 billion each |
| Current offline direct reach | Around 120,000 outlets |
| FY31 offline outlet target | 300,000 outlets |
| Modern trade penetration | 95% |
| Staze revenue | Approaching Rs 1 billion |
These figures show the main areas being tracked by the brokerage and management: brand growth, distribution expansion and operating margins.
Honasa Consumer expects Q2FY27 to build on the momentum seen in the previous quarter. The company expects net sales value to grow in the early thirties year on year.
Mamaearth is expected to deliver high teens year on year growth during the quarter. The company has linked this expectation to stronger brand affinity and a wider offline footprint.
The younger brands are expected to grow faster. Honasa expects their year on year growth to accelerate to around the mid forties during the quarter.
The company is also working to improve EBITDA margins. It expects an early double digit operating margin in Q2FY27, supported by strong year on year gains.
| Q2FY27 expectation | Company view |
|---|---|
| Net sales value growth | Early thirties year on year |
| Mamaearth growth | High teens year on year |
| Younger brand growth | Around mid forties year on year |
| Operating margin | Early double digit |
Offline distribution is an important part of Honasa Consumer's current growth plan. The company currently reaches around 120,000 outlets directly and aims to take that figure to 300,000 by FY31.
The company is also using chemists alongside cosmetics retailers for its offline expansion. This gives Mamaearth and The Derma Co. access to retail points beyond traditional beauty focused stores.
The 95% modern trade penetration reported by management also shows that Honasa has built a broad presence in organised retail. The next stage of growth will depend on how the company scales its direct reach and newer brands.
The stock's recent move also puts attention on how investors are responding to the company's operating update. Similar brokerage driven stock stories, including recent Indian stock rating updates, show how target prices and earnings expectations can influence market attention.
The next focus areas for Honasa Consumer include the pace of sales growth, performance of Mamaearth and The Derma Co., and the contribution from its younger brands.
Investors will also watch the company's progress in offline distribution and whether the planned increase from around 120,000 outlets to 300,000 outlets by FY31 translates into sustained brand growth.
Other factors to monitor include:
HDFC Securities' Rs 550 target price remains the brokerage's view. It does not represent a recommendation from WeloMoney.
Honasa Consumer is the parent company of Mamaearth and The Derma Co. The company also owns brands including Aqualogica, Dr. Sheth's, BBlunt, Reginald and Staze.
Its current strategy involves building larger brands while scaling newer personal care businesses across offline and other distribution channels. The company expects stronger sales growth and an early double digit operating margin in Q2FY27.
The next business update will provide more information on whether these expectations are translating into reported performance, particularly across the company's established and newer brands.
HDFC Securities has maintained a "Buy" rating on Honasa Consumer with a target price of Rs 550. The brokerage highlighted growth across Mamaearth, The Derma Co. and newer brands.
Honasa Consumer shares had gained 54% over six months following a 12% rise on Tuesday after the company's second quarter business update. The stock's year to date gain stood at 63%.
Honasa Consumer expects net sales value growth in the early thirties year on year during Q2FY27. The company expects growth across its focus brands and categories.
Mamaearth is expected to deliver high teens year on year growth in Q2FY27. Honasa Consumer linked the expected growth to stronger brand affinity and a wider offline footprint.
Honasa Consumer aims to increase its offline direct reach from around 120,000 outlets currently to 300,000 outlets by FY31. The company is expanding through chemists and cosmetics retailers.
Honasa Consumer expects an early double digit operating margin in Q2FY27. The company said this would be supported by strong year on year gains during the quarter.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

L&T has begun preliminary work on the New Tashkent International Airport project after receiving a limited notice to proceed.

DLF share price has 41% upside, according to HSBC’s target. Compare Jefferies, CLSA and other broker views on sales, cash flow and valuations.

Divi's Laboratories shares rose 1.01% to Rs 9,242.50 after a positive EU opinion on Eli Lilly's weight loss drug Foundayo. See the growth outlook.

Awfis revenue target exceeds Rs 1,800 crore for FY27, with flexible workspace demand supporting growth. Expansion and execution remain key to watch.

L&T has won a contract worth over Rs 15,000 crore. The client, project scope and execution timeline remain undisclosed, leaving its revenue impact...